Search results
Showing 1 to 4 of 4 results for patiromer calcium
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
CG126/1 | Adding a newer anti-anginal drug to a calcium channel blocker:- What is the clinical and cost effectiveness of adding